
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
Collaboration to promote drug and diagnostics R&D in the fields of metabolic disease and autoimmune neurology.
Decode Health has announced a new phase of its collaboration with Quest Diagnostics. In earlier phases of the collaboration, the two parties developed RNA (transcriptome) sequencing capabilities. In this latest phase, the parties have developed a platform for collecting and storing deidentified consented specimens from individuals participating in research.
Read more about the collaboration






